Notably, APOE ɛ4 confers greater risk of developing MCI in women specifically between 55 and 70 years of age, compared with men.56 In this study, we found an effect of cardiovascular disease risk on tau deposition only among female APOE ɛ4 carriers, who were between 55 and 78 years of age. Here, MAPT is linked to cardiovascular disorder.